Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Genprex Inc (NQ: GNPX )

1.470 -0.130 (-8.13%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 25, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 210,934
Open 1.610
Bid (Size) 1.390 (55)
Ask (Size) 1.570 (20)
Prev. Close 1.600
Today's Range 1.440 - 1.610
52wk Range 1.170 - 4.070
Shares Outstanding 47,898,351
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) to Present at Upcoming Investor Conference
Via Investor Brand Network
Exposures Product Safety
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) CMO to Participate at 33rd Annual Cancer Progress Conference as Expert Panelist
Via Investor Brand Network
Exposures Product Safety

Performance

YTD
-58.00%
-58.00%
1 Month
-11.98%
-11.98%
3 Month
-28.29%
-28.29%
6 Month
-10.91%
-10.91%
1 Year
-59.05%
-59.05%

More News

Read More
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces Shareholder Letter, 2022 Corporate Update
Via Investor Brand Network
Exposures Product Safety
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces Participation in April 2022 Conferences
Via Investor Brand Network
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Opens Acclaim-2 Clinical Trial for Patient Enrollment
Via Investor Brand Network
Genprex Announces the Opening for Enrollment of its Phase 1/2 Acclaim-2 Clinical Trial of REQORSA™ Immunogene Therapy in Combination With Keytruda® to Treat Non-Small Cell Lung Cancer
From Genprex, Inc.
Via Business Wire
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) to Present at 2022 BIO Europe Spring Investor Conference
Via Investor Brand Network
Genprex to Participate in Upcoming Investor Conference in March
From Genprex, Inc.
Via Business Wire
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces Dosing of First Patient in Acclaim-1 Clinical Trial
Via Investor Brand Network
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) to Participate at February Investor Conferences
Via Investor Brand Network
Genprex to Present at Upcoming Investor Conferences Highlighting its Gene Therapies for Cancer and Diabetes
From Genprex, Inc.
Via Business Wire
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Positioned to Expand Oncology Programs, Further Explore Use of ONCOPREX(R) Nanoparticle Delivery System
Via Investor Brand Network
Preclinical Data Show Potential for Use of Genprex’s ONCOPREX® Nanoparticle Delivery System in Treating Colon Cancer
From Genprex, Inc.
Via Business Wire
18 Stocks Moving in Wednesday's Pre-Market Session
Via Benzinga
48 Biggest Movers From Yesterday
Via Benzinga
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) to Accelerate Opening of Acclaim-1 Clinical Trial Sites
Via Investor Brand Network
Genprex to Accelerate Opening of Acclaim-1 Clinical Trial Sites for REQORSA™ Systemic Gene Therapy in Non-Small Cell Lung Cancer
From Genprex, Inc.
Via Business Wire
50 Biggest Movers From Yesterday
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
34 Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
Genprex to Participate in January Investor and Healthcare Conferences to Highlight Company’s Gene Therapies in Cancer and Diabetes
From Genprex, Inc.
Via Business Wire
45 Biggest Movers From Yesterday
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
34 Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.